close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by RENEXXION IRELAND

News headline image
Dr. Falk Pharma and Renexxion Reach Alignment with FDA and EMA on Phase 3 Program for Naronapride in Gastroparesis
From RENEXXION IRELAND
Via GlobeNewswire
News headline image
Renexxion to Present at H.C. Wainwright 28th Annual Global Investment Conference
From RENEXXION IRELAND
Via GlobeNewswire
News headline image
Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis
From RENEXXION IRELAND
Via GlobeNewswire
News headline image
Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial
From RENEXXION IRELAND
Via GlobeNewswire
News headline image
Dr. Falk Pharma and Renexxion Announce Late-Breaker Oral Presentation of Global Phase 2b Gastroparesis Results at Digestive Disease Week (DDW) 2026
From RENEXXION IRELAND
Via GlobeNewswire
News headline image
Renexxion Ireland Ltd. Announces Issuance of Sixth New U.S. Patent Covering New Naronapride Trihydrate Formulation, Dosage Forms, and Treatment of GI Disorders
From RENEXXION IRELAND
Via GlobeNewswire
News headline image
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Completion of Enrollment of the Global Phase 2b Study Evaluating Naronapride in Gastroparesis (MOVE-IT)
From RENEXXION IRELAND
Via GlobeNewswire
News headline image
Renexxion Ireland Ltd. Announces Issuance of Fifth New U.S. Patent Covering Novel Crystal Isoform of Naronapride
From RENEXXION IRELAND
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.